To evaluate the in vivo anti-tumor efficacy of the anti-CCR7 mAb, first we used as hosts the RAG2−/−γc−/− strain, which lacks T, B, and functional NK cells, but has complement activity [42], thus allowing in vivo testing of the MOA characterized in vitro. This evidence concerns the gene CCR7 and neoplasm.